{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:22:33Z","timestamp":1791030153426,"version":"4.1.0"},"reference-count":46,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoporosis is a serious complication of systemic glucocorticoid use. However, while glucocorticoids increase bone resorption in vitro and in vivo, the mechanism(s) of this effect are at present unclear. Recent studies have identified the osteoprotegerin (OPG) ligand (OPG-L) as the final effector of osteoclastogenesis, an action that is opposed by the soluble neutralizing receptor, OPG. Thus, we assessed glucocorticoid regulation of OPG and OPG-L in various human osteoblastic lineage cells using Northern analysis, RT-PCR, and ELISA. Dexamethasone inhibited constitutive OPG messenger RNA (mRNA) steady-state levels by 70\u201390% in primary (MS) and immortalized stromal cells (hMS), primary trabecular osteoblasts (hOB), immortalized fetal osteoblasts (hFOB), and osteosarcoma cells (MG-63). In hFOB cells, dexamethasone inhibited constitutive OPG mRNA steady-state levels in a dose- and time-dependent fashion by 90%, and also suppressed cytokine-stimulated OPG mRNA steady-state levels. Dexamethasone-induced inhibition of OPG mRNA levels was not affected by the protein synthesis inhibitor, cycloheximide, and was shown to be due to inhibition of OPG gene transcription using a nuclear run-on assay. Moreover, dexamethasone also dose dependently (10\u221210m\u201310\u22127m) inhibited constitutive OPG protein concentrations in the conditioned medium of hFOB cells from 2.59 \u00b1 0.02 ng\/ml (control) to 0.30 \u00b1 0.01 ng\/ml (88% inhibition; P &amp;lt; 0.001 by ANOVA). Concurrently, dexamethasone stimulated OPG-L mRNA steady-state levels in MS and hFOB cells by 2- and 4-fold, respectively. Treatment of murine marrow cultures with conditioned medium harvested from dexamethasone-treated MG-63 cells increased tartrate-resistant acid phosphatase (TRAP) activity by 54% (P &amp;lt; 0.005) compared with medium harvested from control-treated cells (in the presence of OPG-L and macrophage colony-stimulating factor). Moreover, dexamethasone (10\u22128m) promoted osteoclast formation in vitro, as assessed by a 2.5-fold increase of TRAP activity in cell lysates (P &amp;lt; 0.001) and the appearance of TRAP-positive multinucleated cells. Our data are thus consistent with the hypothesis that glucocorticoids promote osteoclastogenesis by inhibiting OPG and concurrently stimulating OPG-L production by osteoblastic lineage cells, thereby enhancing bone resorption.<\/jats:p>","DOI":"10.1210\/endo.140.10.7034","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T11:09:28Z","timestamp":1389179368000},"page":"4382-4389","source":"Crossref","is-referenced-by-count":644,"title":["Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1"],"prefix":"10.1210","volume":"140","author":[{"given":"Lorenz C.","family":"Hofbauer","sequence":"first","affiliation":[{"name":"Endocrine Research Unit (L.C.H., F.G., B.L.R., S.K.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gori","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit (L.C.H., F.G., B.L.R., S.K.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Lawrence","family":"Riggs","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit (L.C.H., F.G., B.L.R., S.K.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Lacey","sequence":"additional","affiliation":[{"name":"Amgen, Inc. (D.L.L., C.R.D.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin R.","family":"Dunstan","sequence":"additional","affiliation":[{"name":"Amgen, Inc. (D.L.L., C.R.D.), Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Spelsberg","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology (T.C.S.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Khosla","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit (L.C.H., F.G., B.L.R., S.K.), Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071619520326800_R1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-112-5-352","article-title":"Glucocorticoid-induced osteoporosis: pathogenesis and management.","volume":"112","author":"Lukert","year":"1990","journal-title":"Ann Intern Med"},{"key":"2020071619520326800_R2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/eje.0.1370209","article-title":"Glucocorticoid osteoporosis\u2014mechanisms and management.","volume":"137","author":"Reid","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"2020071619520326800_R3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jcb.240560304","article-title":"Mechanisms of glucocorticoid action in bone cells.","volume":"56","author":"Delany","year":"1994","journal-title":"J Cell Biochem"},{"key":"2020071619520326800_R4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/jbmr.5650111008","article-title":"Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone.","volume":"11","author":"Conaway","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020071619520326800_R5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1359\/jbmr.1997.12.5.734","article-title":"Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2.","volume":"12","author":"Kaji","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2020071619520326800_R6","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/jbmr.5650051206","article-title":"Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro.","volume":"5","author":"Gronowicz","year":"1990","journal-title":"J Bone Miner Res"},{"key":"2020071619520326800_R7","first-page":"1863","article-title":"Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing\u2019s syndrome.","volume":"83","author":"Chiodini","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619520326800_R8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0026-0495(66)90169-7","article-title":"Quantitative microradiographic study of bone remodeling in Cushing\u2019s syndrome.","volume":"15","author":"Riggs","year":"1966","journal-title":"Metabolism"},{"key":"2020071619520326800_R9","first-page":"137","article-title":"Bone histomorphometry in glucocorticoid-induced osteoporosis.","volume":"13","author":"Dempster","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2020071619520326800_R10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanism of their deleterious effects on bone.","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"2020071619520326800_R11","first-page":"3441","article-title":"Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis.","volume":"81","author":"Canalis","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619520326800_R12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"2020071619520326800_R13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identiy of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro.","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"2020071619520326800_R14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071619520326800_R15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-1119(97)00509-X","article-title":"Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.","volume":"204","author":"Tan","year":"1997","journal-title":"Gene"},{"key":"2020071619520326800_R16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1096\/fasebj.12.10.845","article-title":"TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption.","volume":"12","author":"Kwon","year":"1998","journal-title":"FASEB J"},{"key":"2020071619520326800_R17","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"2020071619520326800_R18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin.","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071619520326800_R19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation.","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"2020071619520326800_R20","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL.","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071619520326800_R21","doi-asserted-by":"crossref","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells.","volume":"272","author":"Wong","year":"1997","journal-title":"J Biol Chem"},{"key":"2020071619520326800_R22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"2020071619520326800_R23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"2020071619520326800_R24","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1210\/endo.139.10.6331","article-title":"A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.","volume":"139","author":"Quinn","year":"1998","journal-title":"Endocrinology"},{"key":"2020071619520326800_R25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1006\/bbrc.1998.9394","article-title":"Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.","volume":"250","author":"Hofbauer","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071619520326800_R26","author":"Hofbauer","year":"1998"},{"key":"2020071619520326800_R27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1006\/bbrc.1998.8993","article-title":"Tumor necrosis factor-\u03b1 and -\u03b2 upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells.","volume":"248","author":"Bra\u0308ndstro\u0308m","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071619520326800_R28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1006\/bbrc.1998.9035","article-title":"Osteoprotegerin mRNA is increased by interleukin-1\u03b1 in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells.","volume":"248","author":"Vidal","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071619520326800_R29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/bbrc.1998.8783","article-title":"Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells.","volume":"247","author":"Bra\u0308ndstro\u0308m","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071619520326800_R30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1359\/jbmr.1998.13.2.205","article-title":"Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma.","volume":"13","author":"Hicok","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2020071619520326800_R31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jbmr.5650100203","article-title":"Development and characterization of a conditionally immortalized human fetal osteoblastic cell line.","volume":"10","author":"Harris","year":"1995","journal-title":"J Bone Miner Res"},{"key":"2020071619520326800_R32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/BF02557826","article-title":"Human bone cells in vitro.","volume":"37","author":"Robey","year":"1985","journal-title":"Calcif Tissue Int"},{"key":"2020071619520326800_R33","first-page":"513","article-title":"Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women.","volume":"81","author":"Kassem","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071619520326800_R34","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1021\/bi00640a033","article-title":"RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination.","volume":"16","author":"Lehrach","year":"1977","journal-title":"Biochemistry"},{"key":"2020071619520326800_R35","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1073\/pnas.77.9.5201","article-title":"Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.","volume":"77","author":"Thomas","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071619520326800_R36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/0003-2697(83)90418-9","article-title":"A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity.","volume":"132","author":"Feinberg","year":"1983","journal-title":"Anal Biochem"},{"key":"2020071619520326800_R37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1172\/JCI119880","article-title":"Bone morphogenetic protein-6 production in human osteoblastic cells: selective regulation by estrogen.","volume":"101","author":"Rickard","year":"1998","journal-title":"J Clin Invest"},{"key":"2020071619520326800_R38","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/nar\/11.5.1475","article-title":"Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.","volume":"5","author":"Dignam","year":"1983","journal-title":"Nucleic Acids Res"},{"key":"2020071619520326800_R39","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1126\/science.948759","article-title":"Cortisol stimulation of parathyroid hormone secretion by rat parathyroid glands in organ culture.","volume":"193","author":"Au","year":"1976","journal-title":"Science"},{"key":"2020071619520326800_R40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/joe.0.1590191","article-title":"Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids.","volume":"159","author":"Vidal","year":"1998","journal-title":"J Endocrinol"},{"key":"2020071619520326800_R41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJM199502023320506","article-title":"Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis.","volume":"332","author":"Manolagas","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071619520326800_R42","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/jbmr.5650110802","article-title":"Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis.","volume":"11","author":"Pacifici","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020071619520326800_R43","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease.","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"2020071619520326800_R44","author":"Hofbauer"},{"key":"2020071619520326800_R45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies.","volume":"10","author":"Brattsand","year":"1996","journal-title":"Aliment Pharmacol Ther [Suppl 2]"},{"key":"2020071619520326800_R46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF02311086","article-title":"Modulation of tumor necrosis factor (TNF) receptor expression during monocytic differentiation.","volume":"45","author":"Groppelt-Struebe","year":"1996","journal-title":"Inflamm Res"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/140\/10\/4382\/10375559\/endo4382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/140\/10\/4382\/10375559\/endo4382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:50:49Z","timestamp":1594947049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/140\/10\/4382\/2990346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,1]]},"references-count":46,"aliases":["10.1210\/en.140.10.4382"],"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endo.140.10.7034","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10,1]]}}}